From Wikipedia, the free encyclopedia
Jump to: navigation, search
Vestipitant structure.png
Systematic (IUPAC) name
Clinical data
Legal status
CAS number 334476-64-1 YesY
ATC code None
PubChem CID 9832383
Chemical data
Formula C23H21F10N3O 
Mol. mass 545.416 g/mol
 N (what is this?)  (verify)

Vestipitant is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug,[1][2] and as a treatment for tinnitus[3] and insomnia.[4]

See also[edit]


  1. ^ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy 3 (3): 140–2. doi:10.3816/SCT.2006.n.011. PMID 18632487. 
  2. ^ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR et al. (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 18 (10): 729–50. doi:10.1016/j.euroneuro.2008.06.002. PMID 18657401. 
  3. ^ NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss
  4. ^ Ratti, E; et al. (December 2013). "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.". Sleep (2013) 36 (12): 1823–30. doi:10.5665/sleep.3208. PMC 3825431. PMID 24293756.